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Background: A multicenter European Registry, SEARCH-MI, was instituted in the year 2002 in order to assess
patients’ outcomes and ICD interventions in patients with a previous MI and depressed LV function, treated with an
ICD according to MADIT II results. In this analysis, we evaluate the influence of the time elapsed between last
myocardial infarction (MI) and prophylactic cardioverter defibrillator (ICD) implant on device activations.
Methods: 643 patients with left ventricular dysfunction (mean LVEF 26 ± 5%) and NYHA class I-III were prospectively
followed for 1.8 ± 1.2 years in a multicenter registry. The population was divided into 3 groups according to the
time between last MI and ICD implant: [1] from 40 days to less than 1.5 years; [2] from 1.5 to less than 7 years and
[3] at least 7 years.
Results: The cumulative incidence of ventricular tachyarrhymias and appropriate device therapy (ATP or shock)
were higher in patients implanted longer time from last MI (Gray’s Test p = 0.002 and p= 0.013 respectively). No
significant differences were seen in all cause mortality (Gray’s Test p = 0.618) or sudden cardiac death across the MI
stratification groups (Gray’s Test p = 0.663).
Conclusions: Patients implanted with an ICD longer after the MI have a higher chance of presenting ventricular
tachyarrhythmias and appropriate ICD therapy, while no differences were seen in overall mortality. These
observations may be important for improving patient targeting in sudden death prevention.
Keywords: Cardioverter defibrillator, Myocardial infarction, Registry, Sudden death, Ventricular tachyarrhythmias.Background
The benefit of prophylactic ICD implant in appropriately
selected patients with LV dysfunction has been demon-
strated by prospective randomized clinical trials [1-5].
Nowadays there is increasing interest on two import-
ant issues: first, assessment of therapy in routine clinical
practice [6,7] and second, identification of subgroups of
patients with a higher chance of getting benefit from* Correspondence: giuseppe.boriani@unibo.it
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reproduction in any medium, provided the orICD therapy [8,9] or at the opposite with poor prognosis
after myocardial infarction [10].
Since only 20-30% of patients implanted with an ICD
for primary prevention of SCD present an appropriate
intervention of the device in the first 3-5 years of follow-
up, an analysis of the characteristics of patients who
present an ICD intervention may provide interesting
clinical implications, specifically with regard to improved
patients’ targeting [2,3,8,9,11-14].
In patients with a previous MI associated with
depressed left ventricular ejection fraction a post hoc
analysis of the MADIT II trial (which enrolled patientsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Boriani et al. BMC Cardiovascular Disorders 2012, 12:72 Page 2 of 7
http://www.biomedcentral.com/1471-2261/12/72between 1997 and 2001) showed that mortality rates in
control patients increased as a function of time from
most recent MI, with a greater survival benefit asso-
ciated with ICD implant when the time elapsed from last
MI was ≥18 months [13].
A multicenter European Registry, SEARCH-MI, was
instituted in the year 2002 in order to assess patients’
outcomes and ICD interventions in patients with a pre-
vious MI and depressed LV function, treated with an
ICD according to MADIT II results. The interim ana-
lysis of MADIT II-like patients enrolled in SEARCH MI
registry was published in 2009 [11]. In this analysis, of
the full cohort of patients enrolled in SEARCH MI we
evaluate the influence of the time elapsed between last
MI and prophylactic ICD implant on device activations.Methods
The SEARCH-MI registry was designed as a multi-
centre, prospective, observational study, sponsored by
Medtronic Inc. after publication of MADIT-II study [2].
The only inclusion criteria applicable to SEARCH MI
registry were those related to the MADIT-II trial: all
consecutive patients with previous MI one month or
more before entry, LVEF lower or equal to 30%, without
coronary revascularization within the preceding 3
months. Exclusion criteria were: implantation of ICD as
secondary prevention of sudden death, age <18 years,
unwillingness or inability to participate in data collection
and any condition listed as class III in guidelines for de-
fibrillator implantation. There was no upper age-limit.
The protocol was approved by the local ethics com-
mittees where required by national law and all patients
gave their informed consent.
The patients enrolled underwent defibrillator implant-
ation according to standard techniques: single-chamber,
dual-chamber, or biventricular devices were implanted
per treating physician prescription. All the devices were
Medtronic Inc. market-released defibrillators. Device
programming was empirical and programming of ATP in
the fast VT zone according to PainFree study was recom-
mended [15]. Follow-ups were performed accordingly to
standard follow-up visit scheme of participating centres.
No additional procedures beyond regular practice were
required. Data on demographic and clinical characteris-
tics (medical history, LVEF, NYHA class, QRS width,
medications, arrhythmic history) were collected at base-
line. At each follow-up examination, the following pa-
tient related data were collected: clinical status, NYHA
class, heart failure and other-related hospitalizations,
drug therapy changes, atrial fibrillation occurrence. The
following device-derived data were also reported: ven-
tricular arrhythmia documented by the ICD, ICD inter-
ventions, percentage of ventricular pacing.The cause of death was provided by the attending
physician or collected from clinical records or from
interview of witnesses. Death was classified according to
the following scheme: death occurring in the first hour
from the onset of symptoms was defined as sudden
death; death resulting from a cardiac event was defined
as cardiac death. unwitnessed death was classified as
sudden. To classify unreported mortality and patients
lost to follow-up, patient’s information was retrieved
from the regional demographic service.
Occurrence of ventricular tachyarrhythmias, ICD
intervention, and other clinical data were prospectively
collected. The time to the first appropriate treatment for
ventricular arrhythmia was defined as time from implant
to either intervention with anti-tachycardia pacing
(ATP) or ICD shocks. Classification of spontaneous epi-
sodes and ICD therapies (both appropriate and inappro-
priate) stored in the device memory was adjudicated by
a committee of five physicians in a blinded review
process based on an internet platform (Web-EGM data-
base). Each episode was independently reviewed by at
least two physicians. In the case of disagreement, a third
expert contributed to the final adjudication. Arrhythmic
events were reported separately as appropriate detec-
tions and appropriate therapies to avoid bias from
devices programmed in monitoring status.
The population was divided into the following 3 groups
according to the time elapsed between last MI and
prophylactic ICD implant: Group 1 (from more than 40
days to less than 1,5 years), Group 2 (from 1.5 years to less
than 7 years) and Group 3 (at least 7 years after last MI).
This grouping was based first on the median (2557 days, 7
years) and then given the results from the MADIT II post-
hoc analysis [13], an additional cut-point corresponding to
1.5 years after last MI was also included.Statistical analysis
Descriptive statistics were used to describe the patient
population. Comparisons between the baseline character-
istics were performed by chi-square test for categorical
variables and ANOVA for continuous variables. Cox re-
gression models was used to assess the relationship be-
tween time from MI (as a continuous variable) and
outcomes, results are reported as hazard ratios and 95%
confidence intervals (CI). The cumulative incidences of
outcomes from implant were calculated with all deaths
included as competing outcomes and compared across the
time since MI strata using Gray’s test [16]. In the calcula-
tion of cumulative incidence, only patients alive or lost at
the end of follow up were censored. All probability values
are two-tailed and a P-value< 0.05 was considered statisti-
cally significant. No adjustments to the p-values for mul-
tiple testing were made. All analyses were conducted
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analysis that was conducted using R 2.13.1.
Results
Seven hundred fifty seven patients were prospectively en-
rolled from 68 centres across 5 countries with the majority
of patients enrolled from Italy (73%). For 114 patients the
date of the MI was not known, since the MI had been si-
lent. These patients have been excluded in the present
analysis. Table 1 shows patient characteristics at baseline
(in proximity to ICD implant date) in the cohort of 643
patients and in the 3 groups of patients stratifiedTable 1 Baseline patients’ characteristics in the cohort of 643
according to the time elapsed from last MI
All Time from MI>
and<1,5 y
N=643 N=158
Age, years }
Mean (±SD) 66.7 (±9.4) 66.4 (±11.1
Male } 568 (88.3%) 129 (81.6%
NYHA
I 55 (8.6%) 12 (7.6%
II 315 (49.3%) 73 (46.5%
III 256 (40.1%) 65 (41.4%
IV } 13 (2.0%) 7 (4.5%
LVEF, %
Mean (±SD) 25.9 (±5.0) 26.2 (±5.1)
Median (IQR) 26 (23, 30) 26 (24, 3
History of permanent
atrial fibrillation }
46 (7.2%) 8 (5.1%
LBBB 168 (26.1%) 32 (20.3%
Hypertension 301 (48.6%) 79 (52.0%
Diabetes 182 (29.4%) 47 (30.9%
CABG } 239 (37.2%) 33 (20.9%
PTCA } 247 (38.4%) 86 (54.4%
Amiodarone 154 (24.2%) 33 (21.2%
Statins 319 (49.8%) 78 (49.7%
Diuretics 545 (85.0%) 137 (86.7%
Beta blockers 497 (77.8%) 128 (81.5%
ACE inhibitors 507 (79.1%) 131 (82.9%
Angiotensin II receptor inhibitors 52 (8.2%) 12 (7.7%
Single-chamber ICD 341 (53.0%) 92 (58.2%
Dual-chamber ICD 173 (26.9%) 36 (22.8%
CRT-ICD 129 (20.1%) 30 (19.0%
Time from last MI, years
Median (IQR) 7.0 (1.6, 12.8) 0.5 (0.3, 0
Numbers displayed as n (%), unless otherwise specified.
LVEF = Left Ventricular Ejection Fraction; LBBB = Left Bundle Branch Block; MI =Myoc
} Significant difference (p < 0.05) at chi square test for proportions and ANOVA for maccording to the time elapsed from last MI. Two hundred
and two patients (31%) had a LVEF between 30% and 36%.
A total of 182 arrhythmic events and 74 deaths were
observed over a median follow up of 22 months (inter-
quartile range,11 to 33 months). In Table 2 clinical out-
comes and arrhythmic events by MI stratification group
are reported. As shown, an higher occurrence of detected
and appropriately treated (with ATP or shock) ventricular
tachyarrhythmias was found in patients implanted with
the ICD more than 7 years after last MI.
The cumulative incidence of ventricular tachyarrhyth-
mias (Figure 1A) and appropriate device therapy (ATPpatients and in the 3 groups of patients stratified
40 days
ears
Time from MI≥ 1,5 years
and< 7 years
Time from MI≥ 7 years
N= 171 N=314
) 64.6 (±9.3) 67.9 (±8.4)
) 152 (88.9%) 287 (91.4%)
) 20 (11.8%) 23 (7.3%)
) 89 (52.7%) 153 (48.9%)
) 57 (33.7%) 134 (42.8%)
) 3 (1.8%) 3 (1.0%)
25.6 (±5.0) 26.0 (±4.9)
0) 26 (21, 30) 26 (23, 30)
) 6 (3.5%) 32 (10.2%)
) 46 (26.9%) 90 (28.7%)
) 85 (51.8%) 137 (45.2%)
) 45 (27.3%) 90 (29.7%)
) 64 (37.4%) 142 (45.2%)
) 63 (36.8%) 98 (31.2%)
) 48 (28.2%) 73 (23.5%)
) 91 (53.5%) 150 (47.9%)
) 140 (82.4%) 268 (85.6%)
) 126 (74.1%) 243 (77.9%)
) 129 (75.9%) 247 (78.9%)
) 13 (7.7%) 27 (8.7%)
) 87 (50.9%) 162 (51.6%)
) 54 (31.6%) 83 (26.4%)
) 30 (17.5%) 69 (22.0%)
.9) 4.0 (2.7, 5.5) 12.9 (9.9, 17.4)
ardial Infarction; IQR = Interquartile Range,SD = Standard Deviation
eans.
Table 2 Clinical outcomes and arrhythmic events in the 3 groups of patients, stratified according to the time elapsed
from last MI
Time from MI
> 40 days and< 1,5 years
Time from MI
≥ 1,5 years and< 7 years
Time from MI
≥ 7 years
N= 158 N=171 N=314
Follow-Up, months
Median (IQR) 24 (15, 35) 22 (12, 34) 22 (11, 32)
Detection of at least 1 ventricular tachyarrhythmia (% ) } 33 (20.9%) 45 (26.3%) 104 (33.1%)
Delivery of at least 1 appropriate device therapy (ATP or shock) (%) } 27 (17.1%) 34 (19.9%) 82 (26.1%)
All cause mortality (%) 17 (10.8%) 19 (11.1%) 38 (12.1)
Cardiac mortality (%) 9 (5.7%) 8 (4.7%) 20 (6.4%)
SCD mortality (%) 3 (1.9% ) 3 (1.8%) 9 (2.9%)
} Significant difference between strata, p < 0,05.
SCD= sudden cardiac death.
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time elapsed from last MI (Gray’s Test p = 0.002 and
p = 0.013 respectively). No significant differences were
seen in all cause mortality (Figure 2A, p = 0.618) or sud-
den cardiac death (Figure 2B) across the MI stratification
groups (Gray’s Test p = 0.663).
In a univariate Cox regression analysis of time from
MI (continuous variable = years from MI) yielded a haz-
ard ratio of 1.020 (95% CI 1.003-1.0388), p = 0.024 for
detection of ventricular tachyarrhythmia and of 1.023
(95% CI 1.003-1.044), p = 0.0213 for appropriate device
therapy (ATP or shock). After adjustment for age,
NYHA, permanent AF status at baseline and implanted
device type, time from MI had a hazard ratio of 1.021
(95% CI 1.002, 1.039), p = 0.026 for detection of ven-
tricular tachyarrhythmia and 1.023, (95% CI 1.002,
1.044), = 0.029 for appropriate device therapy (ATP or
shock). For all cause death and sudden cardiac death the
hazard ratio was not statistically significant (adjusted
hazard ratios 1.018 (95% CI 0.990, 1.046) and 1.016 (95%
CI 0.958, 1.078) , respectively).
Discussion
Despite the improvement in treatment of coronary artery
disease and myocardial infarction, survivors of a previous
myocardial infarction are exposed to substantial risk of
life-threatening ventricular tachyarrhythmias which has
been the basis for use of ICD in post-infarction patients
with left ventricular dysfunction [4,5,17,18].
There is a need to evaluate in routine practice, the
outcome of patients with a previous MI, implanted with
an ICD for primary prevention of sudden death. This is
in accordance to the current approach proposed for a
comprehensive validation of effective impact of innova-
tive therapies, based on combination of high quality clin-
ical trials and prospective registries [6]. Either the
potentially worse outcome of patients with a profile
similar to that of controlled trials but not selectedaccording to trial’s exclusion criteria [7], or the need to
verify how treatments affect patient’s outcomes when ap-
plied in an unselected context, are at the basis of current
interest on prospective registries [6].
Our study, which is based on the final results of a pro-
spective multicenter registry [11], suggests that patients
implanted with an ICD with remote myocardial infarction
(7 years or more from last infarction) have higher chance
of presenting an appropriate ICD activation, but do not
present a worse outcome in terms of survival in compari-
son with post infarction patients who carry an ICD, but
have a shorter time elapsed between last myocardial in-
farction and ICD implant. According to these data, the
subgroup of patients with remote MI appears to include
those patients who could get the greatest benefit from im-
plant of a prophylactic ICD. However, these considerations
should take into account that appropriate ICD shocks may
occur more frequently than sudden death, as shown in
patients with nonischemic cardiomyopathy [19] and there-
fore some limitations exists in use of appropriate ICD
shocks as a surrogate of sudden cardiac death. An increase
in appropriate shocks with increasing time after MI has
also been reported for the patients with previous MI en-
rolled in the SCD-HeFT (Sudden Cardiac Death in Heart
Failure Trial) study [20].
In the context of use of ICDs, there is growing interest
on determinants of appropriate ICD therapy in patients
with reduced ventricular function after myocardial in-
farction. This as a way for assessing what patients may
benefit most from implantation of a prophylactic ICD.
This kind of analysis, combined with analysis of relation-
ships between determinants of ICD therapy and death
may be the basis for any attempts to improve patients
targeting. As a matter of fact, in the “routine practice” it
is possible that competing causes of death due to heart
failure, comorbidities or any other cause when occurring
without any prior appropriate ICD intervention, may
preclude benefit from ICD therapy [8].
Figure 1 Cumulative incidence estimates of ventricular
tachyarrhythmias (panel A) and appropriate device therapy
(ATP or shock) (panel B) in patients with a prior MI ≥7years
(dotted red line), MI≥ 1.5 years and <7 years (dashed black
line) and MI >40 days and <1.5 years (blue line).
Figure 2 Cumulative incidence estimates of all cause mortality
(panel A) and sudden cardiac death (panel B) in patients with a
prior MI ≥7years (dotted red line), MI≥ 1.5 years and <7 years
(dashed black line) and MI >40 days and <1.5 years (blue line).
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II trial did not report any relationship between time
from last MI and ICD activations, but showed that mor-
tality rates in control patients increased as a function of
time elapsed from most recent MI, with greater survival
benefit associated with ICD implant when time elapsed
from last MI was ≥18 months [14].
Recently a post-hoc analysis of MUSTT trial found
that the risk of 2- and 5-year arrhythmic death, cardiac
arrest, and all-cause death did not vary as a function of
time from the last recent MI [21]. However, interpretation
of these data should consider that the MUSTT was non-randomized and that the published analysis was based
only on patients who were not treated with an ICD and
who were discharged without antiarrhythmic medications.
In our study we found that the rate of ventricular
tachyarrhythmias and appropriately delivered ICD therap-
ies increase significantly with the time between prior MI
and ICD implant. This suggests that for high risk patients
the longer the time elapsed from last MI the higher is the
tendency to spontaneously develop ventricular tachyar-
rhythmias. Patients with a long survival after MI appear to
have a higher probability of ventricular tachyarrhythmias
(and ICD intervention) probably related to an extensive
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cent MI. The relationship between time from myocardial
necrosis and arrhythmogenesis is confirmed by findings of
the Maastricht study on out-of-hospital cardiac arrest in
the 1990's [22], where the mean interval between previous
MI and occurrence of cardiac arrest was relatively long,
being in average 6.5 years.
In daily clinical practice the question concerning what
the optimal time would be for implanting an ICD in
patients with previous MI and evidence of LV dysfunc-
tion is still open, and has public health implications. A
recent modeling study indicates that benefits of ICD im-
plantation in a relatively early phase after MI (ie, at 60
days) are really modest, when projected at 10 years of
follow up, in comparison to delayed implantation at 6
months or 1 year [23]. Current practice guidelines rec-
ommend ICD implant in patients with previous MI and
left ventricular dysfunction after at least 40 days from
last MI, although the optimal time after the first 40 days
remains undefined. It is unlikely that this question will
be answered with a randomized controlled trial, there-
fore data from observational studies and registries play
an important role. However we have to be cautious
when interpreting the results because of possible selec-
tion bias and confounding factors.
Our registry, while limited to devices made by one
manufacturer, included both single and dual chamber
ICDs and devices with cardiac resynchronization ther-
apy, a very effective therapeutic resource according to a
series of controlled trials [24]. According to MADIT
CRT trial cardiac resynchronization therapy will find a
wider application in post infarction patients, since
NYHA I-II patients will be candidate to resynchroniza-
tion in the presence of wide QRS interval [25]. The
MADIT CRT trial showed that devices with both defib-
rillation capabilities and cardiac resynchronization ther-
apy have additional benefit with regard to heart failure
hospitalization in comparison with ICD only therapy,
but without advantages in terms of survival [25].
Most recently a subanalysis of the MADIT-CRT [26]
demonstrated that among post MI patients the risk of life
threatening ventricular arrhythmias increases as a function
of time elapsed since revascularization procedure. With
this regard we did not perform an analysis of the effects of
revascularization and residual ischemia on ventricular
tachyarrhythmias, ICD discharges and outcomes, since
this is quite problematic in the setting of a registry. We
cannot exclude that observed differences may be due to
confounding factors that were not collected, including the
number of previous MIs, the extent of myocardial scar,
the exact time of revascularization and the evolution of
revascularization practices and MI treatment over time (as
suggested by the data in Table 1, patients with a more re-
mote MI were treated differently from those with a morerecent MI, with regard to use of CABG or PTCA). How-
ever, we need to consider that it is difficult in daily practice
to obtain detailed information on previous revasculariza-
tion procedures as the basis for individualized decision
making. Similarly to MADIT II analysis [13] we did not
considered all the events corresponding to a MI, but we
considered only most recent MI and this may be a limita-
tion of the analysis.
Similarly to other registries we have to consider a
series of limitations typical of study design. Although de-
vice programming according to PainFree study [15] was
suggested, differences in detection and therapy program-
ming among the patient population could have influ-
enced the results. Postmortem ICD interrogations were
not recorded.
Conclusions
Patients implanted with an ICD longer after the MI have
a higher chance of presenting ventricular tachyarrhyth-
mias and appropriate ICD therapy, while no differences
were seen in overall mortality. These observations may
be important for improving patient targeting in sudden
death prevention.
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